TNDM PE Ratio & Valuation,Is TNDM Overvalued

TNDM Relative Valuation

TNDM's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, TNDM is overvalued; if below, it's undervalued.

Historical Valuation

Tandem Diabetes Care Inc (TNDM) is now in the Undervalued zone, suggesting that its current forward PS ratio of 1.36 is considered Undervalued compared with the five-year average of 52.04. The fair price of Tandem Diabetes Care Inc (TNDM) is between 29.14 to 113.18 according to relative valuation methord. Compared to the current price of 22.36 USD , Tandem Diabetes Care Inc is Undervalued By 23.29%.

Relative Value

Fair Zone

29.14-113.18

Current Price：22.36

23.29%

Undervalued

-20.80

31.43

EV/EBITDA

Tandem Diabetes Care Inc. (TNDM) has a current EV/EBITDA of 31.43. The 5-year average EV/EBITDA is 142.61. The thresholds are as follows: Strongly Undervalued below -319.60, Undervalued between -319.60 and -88.50, Fairly Valued between 373.72 and -88.50, Overvalued between 373.72 and 604.82, and Strongly Overvalued above 604.82. The current Forward EV/EBITDA of 31.43 falls within the Historic Trend Line -Fairly Valued range.

-22.98

EV/EBIT

Tandem Diabetes Care Inc. (TNDM) has a current EV/EBIT of -22.98. The 5-year average EV/EBIT is 39.77. The thresholds are as follows: Strongly Undervalued below -191.15, Undervalued between -191.15 and -75.69, Fairly Valued between 155.24 and -75.69, Overvalued between 155.24 and 270.70, and Strongly Overvalued above 270.70. The current Forward EV/EBIT of -22.98 falls within the Historic Trend Line -Fairly Valued range.

1.36

Tandem Diabetes Care Inc. (TNDM) has a current PS of 1.36. The 5-year average PS is 4.24. The thresholds are as follows: Strongly Undervalued below -2.17, Undervalued between -2.17 and 1.03, Fairly Valued between 7.45 and 1.03, Overvalued between 7.45 and 10.65, and Strongly Overvalued above 10.65. The current Forward PS of 1.36 falls within the Historic Trend Line -Fairly Valued range.

10.36

P/OCF

Tandem Diabetes Care Inc. (TNDM) has a current P/OCF of 10.36. The 5-year average P/OCF is 65.42. The thresholds are as follows: Strongly Undervalued below -87.58, Undervalued between -87.58 and -11.08, Fairly Valued between 141.92 and -11.08, Overvalued between 141.92 and 218.42, and Strongly Overvalued above 218.42. The current Forward P/OCF of 10.36 falls within the Historic Trend Line -Fairly Valued range.

12.82

P/FCF

Tandem Diabetes Care Inc. (TNDM) has a current P/FCF of 12.82. The 5-year average P/FCF is -42.41. The thresholds are as follows: Strongly Undervalued below -482.79, Undervalued between -482.79 and -262.60, Fairly Valued between 177.78 and -262.60, Overvalued between 177.78 and 397.97, and Strongly Overvalued above 397.97. The current Forward P/FCF of 12.82 falls within the Historic Trend Line -Fairly Valued range.

Tandem Diabetes Care Inc (TNDM) has a current Price-to-Book (P/B) ratio of 10.98. Compared to its 3-year average P/B ratio of 7.63 , the current P/B ratio is approximately 43.91% higher. Relative to its 5-year average P/B ratio of 10.56, the current P/B ratio is about 4.06% higher. Tandem Diabetes Care Inc (TNDM) has a Forward Free Cash Flow (FCF) yield of approximately -1.72%. Compared to its 3-year average FCF yield of -1.42%, the current FCF yield is approximately 21.15% lower. Relative to its 5-year average FCF yield of -0.41% , the current FCF yield is about 317.05% lower.

10.98

P/B

Median3y

7.63

Median5y

10.56

-1.72

FCF Yield

Median3y

-1.42

Median5y

-0.41

Competitors Valuation Multiple

The average P/S ratio for TNDM's competitors is 4.14, providing a benchmark for relative valuation. Tandem Diabetes Care Inc Corp (TNDM) exhibits a P/S ratio of 1.36, which is -67.04% above the industry average. Given its robust revenue growth of 2.17%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

Revenue Growth

Market Cap

Performance Decomposition

Market capitalization of TNDM decreased by 38.72% over the past 1 year. The primary factor behind the change was an increase in Revenue Growth from 243.97M to 249.25M.

The secondary factor is the Margin Expansion, contributed -10.91%to the performance.

Overall, the performance of TNDM in the past 1 year is driven by Revenue Growth. Which is more sustainable.

2.17%

243.97M → 249.25M

Revenue Growth

-10.91%

-9.53 → -8.49

Margin Expansion

-29.98%

-10.10 → -7.07

P/E Change

-38.72%

37.06 → 22.71

Mkt Cap Growth

People Also Watch

Frequently Asked Questions

Is Tandem Diabetes Care Inc (TNDM) currently overvalued or undervalued?

What is Tandem Diabetes Care Inc (TNDM) fair value?

TNDM's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Tandem Diabetes Care Inc (TNDM) is between 29.14 to 113.18 according to relative valuation methord.

How does TNDM's valuation metrics compare to the industry average?

What is the current P/B ratio for Tandem Diabetes Care Inc (TNDM) as of Jan 08 2026?

As of Jan 08 2026, Tandem Diabetes Care Inc (TNDM) has a P/B ratio of 10.98. This indicates that the market values TNDM at 10.98 times its book value.

What is the current FCF Yield for Tandem Diabetes Care Inc (TNDM) as of Jan 08 2026?

As of Jan 08 2026, Tandem Diabetes Care Inc (TNDM) has a FCF Yield of -1.72%. This means that for every dollar of Tandem Diabetes Care Inc’s market capitalization, the company generates -1.72 cents in free cash flow.

What is the current Forward P/E ratio for Tandem Diabetes Care Inc (TNDM) as of Jan 08 2026?

As of Jan 08 2026, Tandem Diabetes Care Inc (TNDM) has a Forward P/E ratio of -20.80. This means the market is willing to pay $-20.80 for every dollar of Tandem Diabetes Care Inc’s expected earnings over the next 12 months.

What is the current Forward P/S ratio for Tandem Diabetes Care Inc (TNDM) as of Jan 08 2026?

As of Jan 08 2026, Tandem Diabetes Care Inc (TNDM) has a Forward P/S ratio of 1.36. This means the market is valuing TNDM at $1.36 for every dollar of expected revenue over the next 12 months.

TNDM Valuation